HK1114851A1 - Polycyclic indazole derivatives that are erk inhibitors - Google Patents

Polycyclic indazole derivatives that are erk inhibitors

Info

Publication number: HK1114851A1
Authority: HK; Hong Kong
Prior art keywords: indazole derivatives; erk inhibitors; polycyclic; polycyclic indazole; erk
Prior art date: 2005-12-13

Application number

HK08110160.5A

Inventor

Alan Cooper

Yongqi Deng

Gerald W Shipps Jr

Neng-Yang Shih

Hugh Zhu

Robert Sun

Joseph Kelly

Ronald Doll

Yang Nan

Tong Wang

Jagdish Desai

James Wang

Youhao Dong

Vincent S Madison

Li Xiao

Alan Hruza

M Arshad Siddiqui

Ahmed Samatar

Sunil Paliwal

Hon-Chung Tsui

Azim A Celebi

Yiji Wu

Sobhana Babu Boga

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-13

Filing date

2008-09-12

Publication date

2008-11-14

2008-09-12 Application filed by Schering Corp filed Critical Schering Corp

2008-11-14 Publication of HK1114851A1 publication Critical patent/HK1114851A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

HK08110160.5A 2005-12-13 2008-09-12 Polycyclic indazole derivatives that are erk inhibitors HK1114851A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74985605P	2005-12-13	2005-12-13
PCT/US2006/046959 WO2007070398A1 (en)	2005-12-13	2006-12-11	Polycyclic indazole derivatives that are erk inhibitors

Publications (1)

Publication Number	Publication Date
HK1114851A1 true HK1114851A1 (en)	2008-11-14

Family

ID=37969564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK08110160.5A HK1114851A1 (en)	2005-12-13	2008-09-12	Polycyclic indazole derivatives that are erk inhibitors

Country Status (29)

Country	Link
US (1)	US20070191604A1 (en)
EP (1)	EP1966151B1 (en)
JP (1)	JP4881957B2 (en)
KR (1)	KR101417136B1 (en)
CN (1)	CN101370784B (en)
AR (1)	AR056891A1 (en)
AT (1)	ATE527240T1 (en)
AU (1)	AU2006326616B2 (en)
BR (1)	BRPI0619823B8 (en)
CA (1)	CA2633023C (en)
CY (1)	CY1112760T1 (en)
DK (1)	DK1966151T3 (en)
EC (1)	ECSP088550A (en)
ES (1)	ES2372976T3 (en)
HK (1)	HK1114851A1 (en)
HR (1)	HRP20110892T1 (en)
IL (1)	IL192034A (en)
MY (1)	MY149430A (en)
NO (1)	NO341831B1 (en)
NZ (1)	NZ569087A (en)
PE (2)	PE20100562A1 (en)
PL (1)	PL1966151T3 (en)
PT (1)	PT1966151E (en)
RS (1)	RS51981B (en)
RU (1)	RU2442778C9 (en)
SI (1)	SI1966151T1 (en)
TW (1)	TWI344466B (en)
WO (1)	WO2007070398A1 (en)
ZA (1)	ZA200805525B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8546404B2 (en) *	2005-12-13	2013-10-01	Merck Sharp & Dohme	Compounds that are ERK inhibitors
DE602007009932D1 (en) *	2006-02-16	2010-12-02	Schering Corp	PYRROLIDIN DERIVATIVES AS ERK HEMMER
KR20090042779A (en)	2006-06-30	2009-04-30	쉐링 코포레이션	Substituted piperidines that increase p53 activity and the uses thereof
BRPI0812450A2 (en) *	2007-06-05	2019-09-24	Schering Corp	polycyclic indazole derivatives and their use as erk inhibitors for cancer treatment
AR067354A1 (en)	2007-06-29	2009-10-07	Sunesis Pharmaceuticals Inc	USEFUL COMPOUNDS AS INHIBITORS OF RAF QUINASA
MX2010005960A (en) *	2007-11-30	2010-06-11	Schering Corp	Braf biomarkers.
CA2714479A1 (en) *	2008-02-21	2009-08-27	Schering Corporation	Compounds that are erk inhibitors
AU2009222144A1 (en)	2008-02-29	2009-09-11	Array Biopharma Inc.	Pyrazole [3, 4-b] pyridine Raf inhibitors
US20110278332A1 (en) *	2009-03-26	2011-11-17	Protexer, Inc.	Shoe cover removal apparatus
US8637554B2 (en) *	2008-05-07	2014-01-28	The Trustees Of The University Of Pennsylvania	Methods for treating thyroid cancer
US8586543B2 (en) *	2008-08-19	2013-11-19	Merck Sharp & Dohme Corp.	IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
US9229008B2 (en)	2008-08-19	2016-01-05	Merck Sharp & Dohme Corp.	IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011002887A1 (en)	2009-07-02	2011-01-06	Schering Corporation	FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
US8658651B2 (en)	2009-09-30	2014-02-25	Merck Sharp & Dohme Corp.	Compounds that are ERK inhibitors
PE20121172A1 (en)	2009-10-14	2012-09-05	Merck Sharp & Dohme	PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
WO2011123937A1 (en) *	2010-04-06	2011-10-13	University Health Network	Kinase inhibitors and method of treating cancer with same
EP2584903B1 (en)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
EP2608669B1 (en)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) *	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
EP2649065A1 (en)	2010-12-09	2013-10-16	Amgen Inc.	Bicyclic compounds as pim inhibitors
EP2654748B1 (en)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
WO2012129338A1 (en)	2011-03-22	2012-09-27	Amgen Inc.	Azole compounds as pim inhibitors
WO2012145471A1 (en)	2011-04-21	2012-10-26	Merck Sharp & Dohme Corp.	Insulin-like growth factor-1 receptor inhibitors
US8901142B2 (en)	2011-07-26	2014-12-02	Merck Sharp & Dohme Corp.	Fused tricyclic compounds as mTOR inhibitors
US8987274B2 (en)	2011-10-28	2015-03-24	Merck Sharp & Dohme Corp	Macrocycles that increase p53 activity and the uses thereof
US9062071B2 (en)	2011-12-21	2015-06-23	Merck Sharp & Dohme Corp.	Substituted piperidines as HDM2 inhibitors
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
ITMI20120135A1 (en) *	2012-02-02	2013-08-03	Diab Int Ab	PROCEDURE FOR THE PRODUCTION OF PET FOAM AND PET FOAM OBTAINED WITH THIS PROCEDURE
WO2013169858A1 (en)	2012-05-08	2013-11-14	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN103450163B (en) *	2012-05-29	2017-06-23	中国医学科学院药物研究所	Indazole compounds, its preparation method and its medicinal usage
IN2015DN01328A (en)	2012-09-19	2015-07-03	Novartis Ag
AU2013323508B2 (en) *	2012-09-28	2017-11-02	Merck Sharp & Dohme Corp.	Novel compounds that are ERK inhibitors
WO2014100065A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
US9629851B2 (en)	2013-09-20	2017-04-25	Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis	ROCK in combination with MAPK pathway
SG11201601467SA (en)	2013-11-01	2016-05-30	Novartis Ag	Aminoheteroaryl benzamides as kinase inhibitors
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
WO2016095088A1 (en)	2014-12-15	2016-06-23	Merck Sharp & Dohme Corp.	Erk inhibitors
WO2016095089A1 (en)	2014-12-15	2016-06-23	Merck Sharp & Dohme Corp.	Erk inhibitors
US10864179B2 (en)	2015-10-01	2020-12-15	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
JP6931646B2 (en)	2015-10-21	2021-09-08	大塚製薬株式会社	Benlactam compound
WO2017099591A1 (en)	2015-12-07	2017-06-15	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Treatment of inhibitor resistant braf-mutant cancers
WO2017156495A1 (en)	2016-03-11	2017-09-14	Corvus Pharmaceuticals, Inc.	Compounds and methods for modulating bruton's tyrosine kinase
WO2017204626A1 (en)	2016-05-24	2017-11-30	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
AU2017339890A1 (en) *	2016-10-05	2019-04-11	Recurium Ip Holdings, Llc	Spirocyclic compounds
GB201706327D0 (en)	2017-04-20	2017-06-07	Otsuka Pharma Co Ltd	A pharmaceutical compound
AR117398A1 (en)	2018-03-12	2021-08-04	Abbvie Inc	INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE 2
CN114605329B (en) *	2022-03-28	2024-01-26	河南中医药大学	Substituted indazole carboxamides or substituted azaindazole carboxamides FLT3 inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9213077D0 (en)	1992-06-19	1992-08-05	Erba Carlo Spa	Polymerbound taxol derivatives
IL145757A (en) *	2000-02-05	2007-12-03	Vertex Pharma	Pyrazole derivatives and pharmaceutical compositions containing the same
US6897231B2 (en) *	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
MY130778A (en) *	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
JP4648703B2 (en) *	2002-09-05	2011-03-09	アベンティス・ファーマ・ソシエテ・アノニム	Novel aminoindazole derivatives as pharmaceuticals and pharmaceutical compositions containing them

2006
- 2006-12-11 EP EP06845064A patent/EP1966151B1/en active Active
- 2006-12-11 RS RS20110516A patent/RS51981B/en unknown
- 2006-12-11 SI SI200631221T patent/SI1966151T1/en unknown
- 2006-12-11 DK DK06845064.2T patent/DK1966151T3/en active
- 2006-12-11 KR KR1020087016729A patent/KR101417136B1/en active IP Right Grant
- 2006-12-11 CN CN2006800527776A patent/CN101370784B/en active Active
- 2006-12-11 RU RU2008128119/04A patent/RU2442778C9/en active
- 2006-12-11 US US11/636,954 patent/US20070191604A1/en not_active Abandoned
- 2006-12-11 CA CA2633023A patent/CA2633023C/en active Active
- 2006-12-11 BR BRPI0619823A patent/BRPI0619823B8/en not_active IP Right Cessation
- 2006-12-11 JP JP2008545685A patent/JP4881957B2/en not_active Expired - Fee Related
- 2006-12-11 MY MYPI20082076A patent/MY149430A/en unknown
- 2006-12-11 PL PL06845064T patent/PL1966151T3/en unknown
- 2006-12-11 ES ES06845064T patent/ES2372976T3/en active Active
- 2006-12-11 NZ NZ569087A patent/NZ569087A/en not_active IP Right Cessation
- 2006-12-11 WO PCT/US2006/046959 patent/WO2007070398A1/en active Application Filing
- 2006-12-11 AU AU2006326616A patent/AU2006326616B2/en not_active Ceased
- 2006-12-11 PT PT06845064T patent/PT1966151E/en unknown
- 2006-12-11 AT AT06845064T patent/ATE527240T1/en active
- 2006-12-12 AR ARP060105474A patent/AR056891A1/en active IP Right Grant
- 2006-12-12 PE PE2010000279A patent/PE20100562A1/en not_active Application Discontinuation
- 2006-12-12 PE PE2006001592A patent/PE20071095A1/en active IP Right Grant
- 2006-12-12 TW TW095146375A patent/TWI344466B/en not_active IP Right Cessation
2008
- 2008-06-10 IL IL192034A patent/IL192034A/en active IP Right Grant
- 2008-06-13 EC EC2008008550A patent/ECSP088550A/en unknown
- 2008-06-24 ZA ZA200805525A patent/ZA200805525B/en unknown
- 2008-07-11 NO NO20083114A patent/NO341831B1/en not_active IP Right Cessation
- 2008-09-12 HK HK08110160.5A patent/HK1114851A1/en not_active IP Right Cessation
2011
- 2011-11-30 HR HR20110892T patent/HRP20110892T1/en unknown
2012
- 2012-01-04 CY CY20121100006T patent/CY1112760T1/en unknown

Also Published As

Publication number	Publication date
TW200732324A (en)	2007-09-01
AU2006326616A1 (en)	2007-06-21
PE20100562A1 (en)	2010-08-20
SI1966151T1 (en)	2012-02-29
HRP20110892T1 (en)	2011-12-31
RS51981B (en)	2012-02-29
CY1112760T1 (en)	2016-02-10
NZ569087A (en)	2011-09-30
EP1966151A1 (en)	2008-09-10
ATE527240T1 (en)	2011-10-15
CN101370784A (en)	2009-02-18
CA2633023A1 (en)	2007-06-21
BRPI0619823B8 (en)	2021-05-25
PE20071095A1 (en)	2007-11-19
RU2442778C2 (en)	2012-02-20
ZA200805525B (en)	2009-11-25
US20070191604A1 (en)	2007-08-16
IL192034A0 (en)	2008-12-29
BRPI0619823B1 (en)	2020-11-17
NO20083114L (en)	2008-09-12
DK1966151T3 (en)	2012-01-30
CN101370784B (en)	2012-10-10
PL1966151T3 (en)	2012-02-29
BRPI0619823A8 (en)	2019-01-22
WO2007070398A1 (en)	2007-06-21
TWI344466B (en)	2011-07-01
RU2442778C9 (en)	2012-08-10
KR101417136B1 (en)	2014-08-07
ECSP088550A (en)	2008-07-30
KR20080085018A (en)	2008-09-22
AR056891A1 (en)	2007-10-31
AU2006326616B2 (en)	2012-09-06
RU2008128119A (en)	2010-01-20
JP2009519338A (en)	2009-05-14
CA2633023C (en)	2015-11-24
JP4881957B2 (en)	2012-02-22
MY149430A (en)	2013-08-30
ES2372976T3 (en)	2012-01-30
PT1966151E (en)	2011-12-20
NO341831B1 (en)	2018-01-29
EP1966151B1 (en)	2011-10-05
BRPI0619823A2 (en)	2011-11-08
IL192034A (en)	2014-08-31

Publication	Publication Date	Title
IL192034A0 (en)	2008-12-29	Polycyclic indazole derivatives that are erk inhibitors
IL198247A0 (en)	2009-12-24	Indazole derivatives useful as l-cpt1 inhibitors
TWI370127B (en)	2012-08-11	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ZA200710951B (en)	2008-08-27	Piperidinyl-substituted isoquinolone derivatives as Rhokinase inhibitors
SI1934236T1 (en)	2013-02-28	Heterobifunctional pan-selectin inhibitors
IL185185A0 (en)	2007-12-03	Azolylacylguanidines as ??-secretase inhibitors
ZA200807457B (en)	2009-09-30	Pyrrolidine derivatives as ERK inhibitors
HK1114380A1 (en)	2008-10-31	Pyrrolopyrazoles as kinase inhibitors
IL221573A0 (en)	2012-10-31	Imidazoquinolines as lipid kinase inhibitors
IL190078A0 (en)	2008-08-07	Kinase inhibitors
HK1105592A1 (en)	2008-02-22	Aryl-pyridine derivatives as 1-beta-hsd1 inhibitors
HK1107348A1 (en)	2008-04-03	Indozolone derivatives as 11b-hsd1 inhibitors
SI1943243T1 (en)	2011-04-29	Kinase inhibitors
EP1968581A4 (en)	2009-05-27	Tetracyclic kinase inhibitors
IL189112A0 (en)	2008-08-07	NOVEL HETEROCYCLIC NF-kB INHIBITORS
GB0516967D0 (en)	2005-09-28	Inhibitors
ZA200803287B (en)	2009-10-28	Kinase inhibitors
IL189985A0 (en)	2008-08-07	Kinase inhibitors
ZA200706212B (en)	2008-06-25	Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Legal Events

Date	Code	Title	Description
2023-07-07	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20221209